Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 9:31 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 6,915 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Stimulation Clear all

Conditions: Gastric Cancer
Interventions: filgrastim, recombinant interferon alfa, docetaxel, doxorubicin hydrochloride, fluorouracil, hydroxyurea; Biological · Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2004
U.S. locations: 24
States / cities: Denver, Colorado • Chicago, Illinois • Peoria, Illinois + 18 more

Conditions: Anemia of Chronic Kidney Disease
Interventions: Erythropoiesis-Stimulating Agent (ESA), Vadadustat; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 353 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 18
States / cities: Montgomery, Alabama • Hartford, Connecticut • Middlebury, Connecticut + 9 more

Conditions: Leukemia, Lymphoma
Interventions: filgrastim, pegfilgrastim, rituximab, sargramostim, cyclophosphamide, mitoxantrone hydrochloride, pentostatin, fluorescence in situ hybridization, gene rearrangement analysis, polymerase chain reaction, protein expression analysis, flow cytometry, biopsy; Biological · Drug · Genetic + 2 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Posttraumatic Stress Disorder
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cerebrovascular Accident
Interventions: Fast Walking with Fast Functional Electrical Stimulation (FES) Training, Fast Walking; Device · Other
Lead sponsor: Emory University; Other
Eligibility: 30 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: PD - Parkinson's Disease
Interventions: Medtronic Percept Deep Brain Stimulation (cDBS), Medtronic Percept Deep Brain Stimulation (daytime aDBS), Medtronic Percept Deep Brain Stimulation (nighttime aDBS); Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Renal Colic, Kidney Stones, Urolithiasis, Hypocitraturia
Interventions: Commercial AR/VR Headset with Calming App, Pharmacologic Standard of Care Alone; Device · Other
Lead sponsor: Community Medical Center, Toms River, NJ; Other
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Toms River, New Jersey

Conditions: Multiple Sclerosis, Neuropathic Pain
Interventions: Active tDCS using tDCS device, SHAM tDCS using tDCS device; Device
Lead sponsor: Thorsten Rudroff; Other
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: HER2-positive Early-stage Breast Cancer
Interventions: Trastuzumab, Pertuzumab, Docetaxel, Carboplatin; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Elizabeth, New Jersey • Hamilton, New Jersey • Long Branch, New Jersey + 4 more

Conditions: Failed Back Surgery Syndrome, Pain, Back Pain
Interventions: Precision Spinal Cord Stimulator, Back Surgery; Device · Procedure
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 13
States / cities: La Jolla, California • Savannah, Georgia • Bloomington, Illinois + 7 more

Conditions: Normal Physiology
Interventions: SQUID MEG, OPM MEG; Device
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2032
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Bipolar Disorder, Bipolar and Related Disorders, Veterans, Suicide, Suicidal Ideation, Mental Disorders
Interventions: Soterix 1x1 tES mini-CT; Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 21 Years and older
Enrollment: 138 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2031
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Apraxia of Speech, Aphasia, Cerebrovascular Accident
Interventions: Normal Auditory Feedback, Masked Auditory Feedback, Altered Auditory Feedback; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: MCI
Interventions: Active tES, Cognitive Interventions; Device · Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 45 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Lower Extremity Amputee, Diabetic Peripheral Neuropathy
Interventions: Implanted Multi contact stimulating electrode and intramuscular electromyography recording electrode; Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Dilated Cardiomyopathy, Ischemic Cardiomyopathy
Interventions: BiVP, AAI Pacing; Device
Lead sponsor: Henry M. Spotnitz; Other
Eligibility: Not listed
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Alcoholism
Interventions: Transcranial Magnetic Stimulation (rTMS), Sham (SS); Device
Lead sponsor: Nassima Ait-Daoud Tiouririne; Other
Eligibility: 22 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Stroke, Traumatic Brain Injury, Multiple Sclerosis
Interventions: Functional Electrical Stimulation, Normal care; Device
Lead sponsor: Casa Colina Hospital and Centers for Healthcare; Other
Eligibility: 18 Years to 80 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Pomona, California

Conditions: Non-Hodgkin Lymphoma, Hodgkin Disease
Interventions: G-CSF plus plerixafor, rituximab; Drug · Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Chronic Kidney Disease Stages 3-5
Interventions: Ergocalciferol supplementation; Drug
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Reproductive Disorder
Interventions: kisspeptin 112-121, GnRH; Drug
Lead sponsor: Stephanie B. Seminara, MD; Other
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: filgrastim, dexamethasone, melphalan, thalidomide; Biological · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: New York, New York

Conditions: Major Depression, Healthy Participants
Interventions: Sham iTBS, TMS, D-cycloserine, Dextromethophan, Placebo; Device · Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Blood Pressure, Low Back Pain, Hypertension
Interventions: Permanent Epidural Spinal Cord Stimulation; Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 89 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 1
States / cities: Birmingham, Alabama

Search by objective public record fields.

Comparison of Combination Chemotherapy Regimens in Treating Patients With Advanced Stomach Cancer

To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis

Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer

Use of Repetitive Transcranial Magnetic Stimulation (rTMS) in Chronic Posttraumatic Stress Disorder (PTSD)

Stroke Gait Rehabilitation Using Functional Electrical Stimulation

Simplified, Scalable, 24-hour Adaptive DBS in Parkinson's Disease

The Use of AR / VR in Patients Presenting to the ED With Renal Colic

Transcranial Direct Current Stimulation to Lower Neuropathic Pain in People With Multiple Sclerosis

Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer

Spinal Cord Stimulation With Precision® System Versus Reoperation for Failed Back Surgery Syndrome

Characterization of an Optically Pumped Magnetometer (OPM) Magnetoencephalography (MEG) Array

Targeted Alternating Current and Cognitive Training Intervention for Cognitive Control in Bipolar Disorders

Auditory Masking Effects on Speech Fluency in Aphasia and Apraxia of Speech

Personalized Closed-Loop Brain Stimulation for Patients With Mild Cognitive Impairment

Functional and Neuroprotective Effects of Restoring Lower Limb Sensation After Diabetic Peripheral Neuropathy

Optimized Biventricular Pacing Allograft Recipients

Transcranial Magnetic Stimulation (TMS) Treatment for Alcohol Use Disorder

Comparison of Gait Metrics in Patients With Stroke, Traumatic Brain Injury, and Multiple Sclerosis

The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD)

Effects of Ergocalciferol on Erythropoetin Stimulating Agent Dose

Recall by Genotype: Neuropeptide Stimulation

Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis

Synaptic Mechanisms of Intermittent Theta Burst Stimulation for Major Depressive Disorder

Therapeutic Mechanisms of Epidural Spinal Cord Stimulation